Canopy Growth Corp (TSE:WEED – Get Free Report) Director Terry Yanofsky sold 14,920 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of C$1.29, for a total transaction of C$19,246.80. Following the completion of the transaction, the director owned 77,333 shares in the company, valued at C$99,759.57. The trade was a 16.17% decrease in their position.
Canopy Growth Trading Down 3.8%
WEED stock traded down C$0.05 during midday trading on Wednesday, reaching C$1.27. 1,422,628 shares of the company’s stock traded hands, compared to its average volume of 1,569,084. The company has a debt-to-equity ratio of 40.27, a current ratio of 3.04 and a quick ratio of 2.32. Canopy Growth Corp has a fifty-two week low of C$1.18 and a fifty-two week high of C$3.28. The business has a 50-day moving average price of C$1.34 and a two-hundred day moving average price of C$1.40. The company has a market capitalization of C$537.26 million, a P/E ratio of -1.90, a PEG ratio of -0.01 and a beta of 1.63.
Canopy Growth (TSE:WEED – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported C($0.03) earnings per share (EPS) for the quarter. Canopy Growth had a negative return on equity of 29.85% and a negative net margin of 73.95%.The business had revenue of C$81.17 million during the quarter. Equities research analysts forecast that Canopy Growth Corp will post -0.69 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Report on Canopy Growth
Canopy Growth Company Profile
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.
Further Reading
- Five stocks we like better than Canopy Growth
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
